Baker BROS. Advisors LP Has $43.05 Million Holdings in Celcuity, Inc. $CELC

Key Points

• Baker BROS. Advisors LP significantly increased its stake in Celcuity, Inc. by 59% in the first quarter, owning 4,257,735 shares worth approximately $43 million.
• The stock has experienced a decline of 6.2%, with current trading around $51.23, compared to a one-year high of $55.44.
• Insider trading activity includes Director David Dalvey selling 100,000 shares for $4.4 million, reducing his ownership by 44.44%.

Baker BROS. Advisors LP grew its stake in Celcuity, Inc. (NASDAQ:CELC - Free Report) by 59.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,257,735 shares of the company's stock after purchasing an additional 1,579,182 shares during the quarter. Celcuity comprises approximately 0.5% of Baker BROS. Advisors LP's holdings, making the stock its 24th largest holding. Baker BROS. Advisors LP owned 11.25% of Celcuity worth $43,046,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the stock. GAMMA Investing LLC lifted its stake in shares of Celcuity by 1,237.4% in the 1st quarter. GAMMA Investing LLC now owns 1,324 shares of the company's stock valued at $131,000 after purchasing an additional 1,225 shares during the period. Gagnon Securities LLC increased its holdings in Celcuity by 3.5% during the 1st quarter. Gagnon Securities LLC now owns 54,310 shares of the company's stock worth $549,000 after purchasing an additional 1,831 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Celcuity by 22.3% during the 4th quarter. JPMorgan Chase & Co. now owns 14,683 shares of the company's stock worth $192,000 after purchasing an additional 2,676 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Celcuity by 16.2% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,725 shares of the company's stock worth $258,000 after purchasing an additional 2,756 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Celcuity by 8.9% during the 1st quarter. Rhumbline Advisers now owns 42,194 shares of the company's stock worth $427,000 after purchasing an additional 3,439 shares in the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.

Insider Transactions at Celcuity

In related news, Director David Dalvey sold 100,000 shares of the firm's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $43.98, for a total value of $4,398,000.00. Following the completion of the sale, the director directly owned 125,000 shares in the company, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 15.78% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on CELC shares. HC Wainwright increased their target price on Celcuity from $50.00 to $66.00 and gave the stock a "buy" rating in a report on Monday, August 18th. Stifel Nicolaus began coverage on Celcuity in a report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price objective for the company. Needham & Company LLC decreased their price objective on Celcuity from $74.00 to $70.00 and set a "buy" rating for the company in a report on Friday, August 15th. Finally, Leerink Partners raised their price objective on Celcuity from $28.00 to $60.00 and gave the company an "outperform" rating in a report on Monday, July 28th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Celcuity presently has a consensus rating of "Buy" and a consensus price target of $56.50.

Celcuity Stock Performance

NASDAQ:CELC traded up $1.22 during mid-day trading on Friday, hitting $55.69. The stock had a trading volume of 831,391 shares, compared to its average volume of 892,075. Celcuity, Inc. has a twelve month low of $7.57 and a twelve month high of $57.48. The stock has a market cap of $2.36 billion, a price-to-earnings ratio of -16.14 and a beta of 0.72. The company's 50 day simple moving average is $34.32 and its 200 day simple moving average is $18.92. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58.

Celcuity (NASDAQ:CELC - Get Free Report) last issued its earnings results on Thursday, August 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.14). On average, equities research analysts forecast that Celcuity, Inc. will post -2.62 earnings per share for the current year.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.